Skip to main content
    O

    Opus Genetics, Inc. (IRD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.04
    +0.06 (+1.51%)

    Market Cap: $384.68M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Opus Genetics, Inc. (IRD) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Opus Genetics are Ocugen (OCGN), Neurogene (NGNE) and Rocket Pharmaceuticals (RCKT). By market cap, Opus Genetics ranks 8th of the 13 companies on this page; Oric Pharmaceuticals (ORIC) is the largest at $814.71M.

    Peer Comparison

    IRD's ROIC of -145.1% is below the peer median of -15.4%, and its revenue growth of -63.1% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Opus Genetics (IRD)$384.68MN/A52.0x0.0%-145.1%-63.1%0.00%
    Ocugen Inc (OCGN)$280.88MN/A54.9x0.0%271.0%11.4%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    Ovid Therapeutics Inc (OVID)$479.38MN/A335.8x0.0%N/A-88.3%0.00%
    Gyre Therapeutics Inc. (GYRE)$471.74MN/A3.8x-22.7%N/A0.7%0.00%
    Regenxbio Inc (RGNX)$505.18MN/A3.1x-113.9%N/A-69.2%0.00%
    Oric Pharmaceuticals Inc (ORIC)$814.71MN/AN/A0.0%N/A0.0%0.00%
    Oculis Holding AG Ordinary shares (OCS)$425.67MN/AN/A0.0%N/A-97.1%0.00%
    Immuneering Corp (IMRX)$240.27MN/AN/A0.0%N/A-99.8%0.00%
    Indaptus Therapeutics Inc (INDP)$422.38MN/AN/A0.0%N/A0.0%0.00%
    Rezolute Inc (RZLT)$353.54MN/AN/A0.0%N/A0.0%0.00%
    Editas Medicine Inc (EDIT)$334.92MN/A5.6x-145.0%-42.3%37.4%0.00%
    Peer median$424.02MN/A5.6x0.0%-15.4%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Opus Genetics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Ocugen Inc (OCGN)
    Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness.
    OCGN competitors
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    Ovid Therapeutics Inc (OVID)
    Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States.
    OVID competitors
    Gyre Therapeutics Inc. (GYRE)
    Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases.
    GYRE competitors
    Regenxbio Inc (RGNX)
    REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable...
    RGNX competitors
    Oric Pharmaceuticals Inc (ORIC)
    ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers.
    ORIC competitors
    Oculis Holding AG Ordinary shares (OCS)
    Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye.
    OCS competitors
    Immuneering Corp (IMRX)
    Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its...
    IMRX competitors
    Indaptus Therapeutics Inc (INDP)
    Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms.
    INDP competitors
    Rezolute Inc (RZLT)
    Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States.
    RZLT competitors
    Editas Medicine Inc (EDIT)
    Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases.
    EDIT competitors

    Frequently Asked Questions About IRD

    Who are Opus Genetics' main competitors?

    The companies most similar to Opus Genetics include Ocugen (OCGN), Neurogene (NGNE), Rocket Pharmaceuticals (RCKT), Ovid Therapeutics (OVID) and Gyre Therapeutics (GYRE), listed from the closest match.

    Who is Opus Genetics' biggest competitor?

    Oric Pharmaceuticals (ORIC) is the largest of the similar companies at $814.71M; Ocugen (OCGN) is the closest match by business profile, size, sector and industry.

    How does IRD stock compare with its competitors?

    IRD's P/S is 52.0x against a peer median of 5.6x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Opus Genetics' competitors pays a higher dividend?

    Opus Genetics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Opus Genetics bigger than its competitors?

    No. Opus Genetics is 8th by market cap among the 13 companies on this page; the largest is Oric Pharmaceuticals (ORIC) at $814.71M.